CAREERS Careers at Sorrento Therapeutics, Inc Sorrento Therapeutics, Inc. is an Equal Opportunity Employer and offers candidates an attractive salary and comprehensive benefits package that includes stock options, medical, dental, life and disability insurance, 401k and paid holidays. Powered by © 2021 Sorrento Therapeutics, Inc. All Rights Reserved. Terms of Use | Forward Looking Statements | Privacy Policy | Cookie Policy | Notices

CAR T / DAR T CAR T (Chimeric Antigen Receptor-T Cell) Sorrento’s cellular therapy programs focus on Chimeric Antigen Receptor-T Cell (CAR T) for adoptive cellular immunotherapy to treat both solid and liquid tumors. The CAR T program includes CD38, CEA and CD123. Sorrento’s CD38 CAR T targets high-expressing CD38 positive cells, which may limit on-target/off-tumor toxicity. The company’s CD38 CAR T candidate is currently being evaluated in multiple myeloma (MM). The program has successfully demonstrated strong preclinical anti-tumor activity in animal models and is currently in phase 1 trial in RRMM. Additionally, Sorrento has reported data from Phase I trials of carcinoembryonic antigen (CEA) directed CAR T program. The company is assessing CD123 CAR T in acute myeloid leukemia (AML). DAR T (Dimeric Antigen Receptor-T Cell) Sorrento utilizes a proprietary knock-out knock-in (KOKI) technology to modify normal healthy donor derived T cells to genetically engineer them to express the dimeric antigen receptor into T-cell receptor (TCR) alpha chain constant region (TRAC). In this manner, TRAC is knocked out and antigen is knocked into its locus. The Dimeric Antigen Receptor (DAR) utilizes a Fab instead of the scFv used by traditional Chimeric Antigen Receptor (CAR) T cells. We believe this DAR has been demonstrated in preclinical studies greater specificity, stability and potency. Chimeric Antigen Receptors (CARs) Current CAR T Cell Technology Next-Gen Dimeric Antigen Receptor (DAR) Technology G-MABTM CAR T / DAR T ADCS ONCOLYTIC VIRUS ABIVERTINIB ADNIC © 2021 Sorrento Therapeutics, Inc. All Rights Reserved. Terms of Use | Forward Looking Statements | Privacy Policy | Cookie Policy | Notices

BOARD OF DIRECTORS Henry Ji Chairman, President and CEO Dorman Followwill Director Kim D. Janda Director David Lemus Director Jaisim Shah Director Robin Smith Director Yue Alexander Wu Director © 2021 Sorrento Therapeutics, Inc. All Rights Reserved. Terms of Use | Forward Looking Statements | Privacy Policy | Cookie Policy | Notices